ST. Joseph's - Northeast is a medicare approved dialysis facility center in Fayetteville, New York and it has 12 dialysis stations. It is located in Onondaga county at 4105 Medical Center Drive, Fayetteville, NY, 13066. You can reach out to the office of ST. Joseph's - Northeast at (315) 329-2580. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. ST. Joseph's - Northeast has the following ownership type - Profit. It was first certified by medicare in July, 2009. The medicare id for this facility is 332667 and it accepts patients under medicare ESRD program.
Name | ST. Joseph's - Northeast |
---|---|
Location | 4105 Medical Center Drive, Fayetteville, New York |
No. of Dialysis Stations | 12 |
Medicare ID | 332667 |
Managed By | Independent |
Ownership Type | Profit |
Late Shifts | No |
4105 Medical Center Drive, Fayetteville, New York, 13066 | |
(315) 329-2580 | |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
NPI Number | 1174760573 |
Organization Name | St. Joseph's - Northeast |
Doing Business As | Sjls, Llc |
Address | 4105 Medical Center Dr Fayetteville, New York, 13066 |
Phone Number | (315) 329-7200 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
NPI Number | 1184654212 |
Doing Business As | St Joseph's Hospital Health Center |
Address | 4105 Medical Center Dr Fayetteville, New York, 13066 |
Phone Number | (315) 329-7200 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
Dialysis patients with Hemoglobin data | 28 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 4 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 60 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 504 |
Percentage of adult patients getting regular hemodialysis at the center | 98 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at ST. Joseph's - Northeast with elevated calcium levels.
Patients with hypercalcemia | 61 |
Hypercalcemia patient months | 512 |
Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
Patients with Serumphosphor | 63 |
Patients with Serumphosphor less than 3.5 mg/dL | 6 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 32 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 20 |
Patients with Serumphosphor greater than 7 mg/dL | 6 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 51 |
Patient months included in arterial venous fistula and catheter summaries | 403 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 70 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 55 |
Hospitalization Rate in facility | 220.8 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 363 |
Hospitalization Rate: Lower Confidence Limit | 139 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at ST. Joseph's - Northeast were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 26 (As Expected) |
Readmission Rate: Upper Confidence Limit | 37.4 |
Readmission Rate: Lower Confidence Limit | 16.7 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at ST. Joseph's - Northeast get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | 1.52 (As Expected) |
SIR: Upper Confidence Limit | 3.38 |
SIR: Lower Confidence Limit | .56 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether ST. Joseph's - Northeast's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 47 |
Transfusion Rate in facility | 26.5 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 100.6 |
Transfusion Rate: Lower Confidence Limit | 8.2 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at ST. Joseph's - Northeast lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 264 |
Mortality Rate in facility | 19.4 (As Expected) |
Mortality Rate: Upper Confidence Limit | 25.9 |
Mortality Rate: Lower Confidence Limit | 14.3 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago
ST. Joseph's - Northeast Location: 4105 Medical Center Drive, Fayetteville, New York, 13066 Phone: (315) 329-2580 |
News Archive
The widespread use of a simplified clinical tool to estimate future coronary risk could lead to the classification of millions of Americans into different risk groups than when using the original, "gold-standard" tool. Millions of patients may have been misclassified into higher-risk groups and therefore potentially over-treated, while others may have ended up in lower-risk groups and therefore potentially under-treated for heart disease. The study-, led by William Gordon from Weill Cornell Medical College in the US and colleagues, is published in the Journal of General Internal Medicine-, published by Springer.
Micheál Martin TD, Minister for Health and Children has given further details of the new European Health Insurance Card.
IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed's largest stockholder.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
A new study indicates that children's sleep duration may be influenced by parental sleep duration and confidence, which suggests that efforts to address insufficient sleep among children may require family-based interventions.
› Verified 4 days ago